IL271085B2 - Bacteria for the treatment of disorders - Google Patents

Bacteria for the treatment of disorders

Info

Publication number
IL271085B2
IL271085B2 IL271085A IL27108519A IL271085B2 IL 271085 B2 IL271085 B2 IL 271085B2 IL 271085 A IL271085 A IL 271085A IL 27108519 A IL27108519 A IL 27108519A IL 271085 B2 IL271085 B2 IL 271085B2
Authority
IL
Israel
Prior art keywords
phage
ecolin
genome
genes
bacterium
Prior art date
Application number
IL271085A
Other languages
English (en)
Hebrew (he)
Other versions
IL271085B1 (en
IL271085A (en
Inventor
Dean Falb
Yves Millet
Adam B Fisher
Vincent M Isabella
Jonathan W Kotula
David Lubkowicz
Paul F Miller
Sarah Elizabeth Rowe
Original Assignee
Synlogic Operating Co Inc
Dean Falb
Yves Millet
Adam B Fisher
Vincent M Isabella
Jonathan W Kotula
David Lubkowicz
Paul F Miller
Sarah Elizabeth Rowe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Operating Co Inc, Dean Falb, Yves Millet, Adam B Fisher, Vincent M Isabella, Jonathan W Kotula, David Lubkowicz, Paul F Miller, Sarah Elizabeth Rowe filed Critical Synlogic Operating Co Inc
Publication of IL271085A publication Critical patent/IL271085A/en
Publication of IL271085B1 publication Critical patent/IL271085B1/en
Publication of IL271085B2 publication Critical patent/IL271085B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/202—Pseudochromosomes, minichrosomosomes of bacteriophage origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL271085A 2017-06-21 2018-06-21 Bacteria for the treatment of disorders IL271085B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762523225P 2017-06-21 2017-06-21
US201762523202P 2017-06-21 2017-06-21
US201762552785P 2017-08-31 2017-08-31
US201762552829P 2017-08-31 2017-08-31
US201862614213P 2018-01-05 2018-01-05
US201862624299P 2018-01-31 2018-01-31
PCT/US2018/038840 WO2018237198A1 (en) 2017-06-21 2018-06-21 Bacteria for the treatment of disorders

Publications (3)

Publication Number Publication Date
IL271085A IL271085A (en) 2020-01-30
IL271085B1 IL271085B1 (en) 2024-03-01
IL271085B2 true IL271085B2 (en) 2024-07-01

Family

ID=62909623

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271085A IL271085B2 (en) 2017-06-21 2018-06-21 Bacteria for the treatment of disorders

Country Status (8)

Country Link
US (2) US11879123B2 (enExample)
EP (1) EP3642221A1 (enExample)
JP (3) JP7358245B2 (enExample)
CN (1) CN111655841A (enExample)
AU (2) AU2018290278B2 (enExample)
CA (1) CA3066085A1 (enExample)
IL (1) IL271085B2 (enExample)
WO (1) WO2018237198A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3682008A4 (en) 2017-09-14 2020-12-09 University of Massachusetts GENETICALLY MODIFIED MICRO-ORGANISMS AND THEIR METHODS OF USE
CN108048342B (zh) * 2017-10-26 2021-06-04 中国农业大学 一种耐压益生菌及其食品和制备方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
EP3962506A4 (en) * 2019-05-03 2022-07-13 University Of Massachusetts GENETICALLY MODIFIED MICROORGANISMS AND METHODS OF USE
CN114008070A (zh) * 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸
WO2021127648A1 (en) * 2019-12-19 2021-06-24 Auburn University Microbial ester production
US20230092431A1 (en) * 2020-01-14 2023-03-23 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
CN111235169A (zh) * 2020-02-03 2020-06-05 昆明理工大学 一种GTP环化水解酶I基因folE及应用
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
US20220031771A1 (en) * 2020-07-31 2022-02-03 Iowa State University Research Foundation, Inc. Microencapsulated and chromosome integrated compositions for l-dopa microbiome therapy
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
CN116847860A (zh) * 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
WO2022204406A1 (en) * 2021-03-24 2022-09-29 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
CN113789276B (zh) * 2021-09-15 2023-05-12 千宠堂(福建)生物科技有限公司 一株产β-烟酰胺单核苷酸的植物乳杆菌及其应用
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
CN116555063B (zh) * 2022-01-27 2025-08-08 中国海洋大学 动物双歧杆菌f1-7在降解苯丙氨酸中的应用
CN116179452A (zh) * 2022-07-11 2023-05-30 山东第一医科大学(山东省医学科学院) 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用
JP2025534764A (ja) 2022-10-17 2025-10-17 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するためのフェニルアラニンアンモニアリアーゼ、フェニルアラニントランスポーターおよびｌ－アミノ酸デアミナーゼを発現する組み換え細菌

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183531A1 (en) * 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
CN101068919B (zh) * 2004-11-30 2011-08-10 Aeras全球Tb疫苗基金会 适用于产生和制备重组双链rna核壳的细菌包装菌株及其用途
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
WO2011080505A2 (en) * 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
WO2011106874A1 (en) 2010-03-02 2011-09-09 Functional Technologies Corp. Functional enhancement of microorganisms to minimize production of acrylamide
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
CN104487581B (zh) 2012-06-22 2021-05-28 菲特吉恩公司 用于苯乙烯合成的酶和方法
CA2880620A1 (en) 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
US20150246085A1 (en) 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
WO2014138324A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
BR112017011923A2 (pt) 2014-12-05 2018-02-27 Synlogic Inc bactéria modificada para tratar doenças associadas com hiperamonemia
JP7095993B2 (ja) 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3307870B1 (en) 2015-06-10 2023-08-02 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
EP3377518B1 (en) 2015-11-16 2022-04-13 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183531A1 (en) * 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia

Also Published As

Publication number Publication date
US11879123B2 (en) 2024-01-23
EP3642221A1 (en) 2020-04-29
JP2023123506A (ja) 2023-09-05
IL271085B1 (en) 2024-03-01
IL271085A (en) 2020-01-30
AU2018290278B2 (en) 2022-12-15
JP7639056B2 (ja) 2025-03-04
US20240368531A1 (en) 2024-11-07
CA3066085A1 (en) 2018-12-27
WO2018237198A1 (en) 2018-12-27
AU2023201271A1 (en) 2023-04-06
JP7358245B2 (ja) 2023-10-10
AU2018290278A1 (en) 2019-12-19
JP2025087727A (ja) 2025-06-10
CN111655841A (zh) 2020-09-11
JP2020525012A (ja) 2020-08-27
US20200172857A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US20240368531A1 (en) Bacteria for the treatment of disorders
JP7494345B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
JP7592777B2 (ja) 高フェニルアラニン血症を低減させるように操作された細菌
US20230043588A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US10273489B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11685925B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
JP2020525012A5 (enExample)
AU2016346646B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2016210373A2 (en) Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
JP2018535678A5 (enExample)
CN115335066A (zh) 经工程化以治疗其中草酸盐有害的病症的细菌
US20210161976A1 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier